Cofepris issues alert for Dobutamine injectable solution medication

The Federal Commission for the Protection against Sanitary Risks (Cofepris) alerted health professionals and the health sector to immobilize and suspend, as a preventive measure, the use and administration of Dobutamine, intravenous injectable solution 250 mg/5 mL with any lot number, distributed by Biosistemas y Seguridad Privada, SA de CV and manufactured by Health Biotech Limited.

Through a statement, Cofepris details that the precautionary measure is issued in order to avoid and/or control any health risk, since Cofepris keeps said product under investigation, after at least three states reported irregularities.

“This health authority recommends suspending the use and administration of this product and immobilizing it preventively, carrying out the storage and conservation instructions indicated on the label, until what is appropriate is determined,” he highlights.

Explain that if you have used Dobutamine with the aforementioned characteristics and present any symptoms, adverse reactions or discomfort, you are invited to report it to the following online link or to the email: [email protected].

If new evidence is identified, Cofepris will inform in order to prevent this product or any other, as well as companies and establishments, from failing to comply with health legislation and representing a risk to the health of the population.

You can also read: Cofepris alert for the falsification of oncological drugs

jcp